ZP6590
/ Zealand Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 17, 2023
Zealand Pharma Announces Financial Results for the First Half of 2023
(GlobeNewswire)
- "ZP6590, GIP analog. Zealand expects to complete pre-clinical activities in 2023 and advance this program into first-in-human clinical trials in the first half of 2024."
New P1 trial • Metabolic Disorders • Obesity
1 to 1
Of
1
Go to page
1